Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7), an exploratory analysis of a randomised controlled trial
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Abstract
A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the United Kingdom from November 2020. Here we report efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19, against this variant.
Description
Keywords
Journal Title
The Lancet
Conference Name
Journal ISSN
0140-6736
Volume Title
397
Publisher
Elsevier
Publisher DOI
Rights and licensing
Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
MRC (MC_PC_19027)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
COVID-19 Genomics UK is supported by funding from the Medical Research Council, part of UK Research and Innovation, the NIHR, and Genome Research, operating as the Wellcome Sanger Institute.